

# Resource Summary Report

Generated by [dkNET](#) on Sep 21, 2026

## RAW 264.7

RRID:CVCL\_0493

Type: Cell Line

---

### Proper Citation

Ubigen Cat# YC-C020, RRID:CVCL\_0493

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_0493](https://web.expasy.org/cellosaurus/CVCL_0493)

**Proper Citation:** Ubigen Cat# YC-C020, RRID:CVCL\_0493

**Description:** Cell line RAW 264.7 is a Cancer cell line with a species of origin Mus musculus (Mouse)

**Sex:** Male

**Disease:** Mouse leukemia

**Defining Citation:** [PMID:212198](#), [PMID:3792703](#), [PMID:16948499](#), [PMID:19057837](#), [PMID:19144319](#), [PMID:22735334](#), [PMID:23430347](#), [PMID:25277546](#), [PMID:25504905](#), [PMID:29889899](#), [PMID:31220119](#), [PMID:31947698](#), [PMID:33389257](#)

**Comments:** Miscellaneous: PubMed=23430347 has a different value for STR 6-4 (17) than that of NIST (18) due to a change in the marker motif (personal communication of Almeida, Jamie L.), Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257), Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).

**Category:** Cancer cell line

**Organism:** Mus musculus (Mouse)

**Name:** RAW 264.7

**Synonyms:** RAW264, RAW2647, RAW264.7, RAW-264.7, Raw 264.7, Raw264.7

**Cross References:** BTO:BTO\_0003292, CLO:CLO\_0008753, CLO:CLO\_0051424, EFO:EFO\_0001231, MCCL:MCC:0000390, CLDB:cl4110, CLDB:cl7129, Abcam:ab275474, AddexBio:C0003008/444, ATCC:TIB-71, BCRC:60001, BCRJ:0212, BioSample:SAMN11397665, CCRID:1101MOU-PUMC000146, CCRID:3101MOUSCSP5036, CCRID:3101MOUTCM13, CCRID:4201MOU-

CCTCC00143, CCRID:6101MOU-CERC000109, CCTCC:GDC0143, ChEMBL-Cells:ChEMBL3307977, ChEMBL-Targets:ChEMBL612557, CLS:400319, ECACC:91062702, FCS-free:225-5-468-2-3-3, IBRC:C10072, ICLC:ATL02001, IZSLER:BS TCL 177, KCB:KCB 200603YJ, KCLB:40071, Lonza:674, MeSH:D000067996, MetaboLights:MTBLS23, MetaboLights:MTBL1140, MetaboLights:MTBLS636, MetaboLights:MTBLS696, NCBI\_Iran:C639, PRIDE:PXD000984, PRIDE:PXD001293, PRIDE:PXD001905, PRIDE:PXD001935, PRIDE:PXD003545, PubChem\_Cell\_line:CVCL\_0493, TOKU-E:2976, TOKU-E:4095, Ubigene:YC-C020, Wikidata:Q28335461

**ID:** CVCL\_0493

**Vendor:** Ubigene

**Catalog Number:** YC-C020

**Hierarchy:** cvcl\_4478

**Record Creation Time:** 20250130T072708+0000

**Record Last Update:** 20260920T011507+0000

---

## Ratings and Alerts

No rating or validation information has been found for RAW 264.7.

No alerts have been found for RAW 264.7.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 16038 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Li R, et al. (2026) Porcine decellularized nerve matrix hydrogel attenuates neuroinflammation after peripheral nerve injury by inhibiting the TLR4/MyD88/NF- $\kappa$ B axis. Neural regeneration research, 21(3), 1222.

Fu Z, et al. (2026) Photo-Empowered Macrophage-Based Drug Delivery System Overcomes Motility Suppression and Significantly Enhances Deep Tumor Drug Delivery. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(5), e15349.

Zhang Y, et al. (2026) Mechanical stress attenuates the metabolic reprogramming and M1 polarization of macrophages by upregulating integrin subunit alpha D. Cellular signalling, 146, 112666.

- Durmus GT, et al. (2026) Resolvin E1 and Maresin 1 Attenuate Nucleotide-Binding Oligomerization Domain-Like Receptor Protein 3-Associated Inflammation and Invasion in Oral Squamous Cell Carcinoma. *The American journal of pathology*, 196(8), 1777.
- Pei Z, et al. (2026) STAT3 interference-driven nanomodulators reverse lipid metabolism-associated chemoresistance and potentiate metalloimmunotherapy in breast cancer. *Cell reports. Medicine*, 7(6), 102844.
- Peng H, et al. (2026) Fucosyltransferase 8-mediated core fucosylation of krüppel-like factor 6 exacerbates myocardial ischaemia/reperfusion injury via promoting macrophage M1 polarization. *British journal of pharmacology*, 183(17), 5284.
- Liu Q, et al. (2026) ZNF831 suppresses triple-negative breast cancer progression through NLRP3-associated pyroptotic signaling and M1-like macrophage phenotypic remodeling. *Breast cancer research : BCR*, 28(1).
- Zhao XY, et al. (2026) Toxoplasma gondii effector MAF1 blocks mouse AIM2 inflammasome activation by inhibiting mtDNA release. *Journal of immunology (Baltimore, Md. : 1950)*, 215(2).
- Aobulikasimu N, et al. (2026) Galangin-loaded biomimetic dendritic cells membrane nanovaccine reprograms the ovarian cancer microenvironment via Stat3/IDO1/AhR axis to boost immunotherapy. *Materials today. Bio*, 37, 102924.
- Tang L, et al. (2026) High Glucose Triggers Macrophage Senescence Through Mitochondrial Dysfunction and Mitophagy Impairment. *Cell biochemistry and function*, 44(4), e70211.
- Zhao D, et al. (2026) Gut microbiota-derived cholic acid ameliorates lung inflammation in bronchopulmonary dysplasia through modulation of macrophage function. *iScience*, 29(4), 115398.
- Rahman MM, et al. (2026) Ecto-5'-nucleotidase/CD73 reduces COX-2 expression in activated macrophages. *Scientific reports*, 16(1), 4666.
- Contreras PS, et al. (2026) Differential contribution of TFE3 isoforms to cell motility and invasion. *EMBO reports*, 27(2), 471.
- Zhao L, et al. (2026) Icariin alleviates corneal neovascularization by regulating inflammation through inhibition of macrophage polarization and the NF- $\kappa$ B pathway. *Journal of translational medicine*, 24(1).
- Nguyen N, et al. (2026) Transcranial microtesla magnetic fields suppress neuroinflammation and neuronal oxidative stress burden. *iScience*, 29(1), 114425.
- Han J, et al. (2026) Cascade-triggered oral gelatin-alginate micro-nano carriers integrate dual targeting and microbiota restoration for anti-Salmonella therapy. *International journal of biological macromolecules*, 356, 151581.
- Yuanhui Y, et al. (2026) Exploring the Anti-Inflammatory Mechanism of Boletus edulis Based on UPLC-MS/MS Combined With Network Pharmacology, Molecular Docking, and Experimental Validation. *Chemistry & biodiversity*, 23(3), e03316.

Li B, et al. (2026) Targeted Thrombolysis via CCR2-Engineered Macrophage-Mimicking Microbubbles Safely Ablates Venous, Arterial, and Microvascular Thrombosis. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(23), e24002.

Schneider P, et al. (2026) Biodegradable Carbonate Nanogels Loaded with Anti MFAP-5 siRNA for Anti-stromal Therapy of Hepatocellular Carcinoma. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(21), e10006.

Liu X, et al. (2026) TGM2 Aggravates Acute Pancreatitis by Impairing Macrophage Efferocytosis Through Inhibition of the STAT6-GAS6 Axis. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(24), e20739.